Filtered By:
Cancer: Renal Cell Carcinoma
Management: Medicare

This page shows you your search results in order of date.

Order by Relevance | Date

Total 1 results found since Jan 2013.

Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma
CONCLUSIONSSunitinib and sorafenib might be associated with an increased risk of cardiovascular events and particularly stroke. Cancer 2015. © 2015 American Cancer Society.
Source: Cancer - October 6, 2015 Category: Cancer & Oncology Authors: Sekwon Jang, Chaoyi Zheng, Huei‐Ting Tsai, Alex Z. Fu, Ana Barac, Michael B. Atkins, Andrew N. Freedman, Lori Minasian, Arnold L. Potosky Tags: Original Article Source Type: research